Navigation Links
Experimental Drug May Dampen Severe Asthma
Date:3/4/2009

In small studies, mepolizumab reduced number of exacerbations,,,,

WEDNESDAY, March 4 (HealthDay News) -- A new type of asthma therapy might be especially helpful for people with severe asthma who often have to take oral steroids to control their symptoms.

The drug is called mepolizumab, and two small studies in the March 5 issue of the New England Journal of Medicine have found that, when taken regularly, it can reduce asthma exacerbations. Additionally, people taking the drug had lower levels of eosinophils, a type of white blood cell that has been implicated as a potential cause of asthma.

"This is a new treatment which substantially reduces the risk of asthma attacks in a severe asthma population," said the senior author of one of the studies, Dr. Ian Pavord, a consultant physician and an honorary professor of medicine at Glenfield Hospital, University Hospitals of Leicester, England.

Dr. Paul O'Byrne, the senior author of the other study, added that "we now have a likely new treatment modality that will improve outcomes and reduce exacerbations in severe prednisone-dependent asthma, and this is not a small population -- it's probably 2 to 4 percent of the asthmatic population." O'Byrne is chairman of the Department of Medicine at McMaster University and executive director of the Firestone Institute for Respiratory Health at St. Joseph's Hospital in Hamilton, Ontario, Canada.

Both studies were funded by GlaxcoSmithKline, the pharmaceutical company that is developing the drug.

He said that mepolizumab works by blocking a protein called interleukin-5, which is essential for the development of eosinophils. Eosinophils have long been implicated in asthma, though their exact role remains unclear. However, scientists do know that when an asthma exacerbation occurs, eosinophil levels usually rise.

In the first study, Pavord and his colleagues randomly placed 61 people with severe asthma on either 750 milligrams of mepolizumab or a placebo for a year. The drug and placebo were administered intravenously once a month for a year.

Over the study period, those on mepolizumab had fewer asthma exacerbations than those on placebo -- 2 versus 3.4. People taking the drug also reported a greater improvement in their quality of life than did people taking the placebo.

The second study was smaller, including just 20 patients. Nine received 750 mg of mepolizumab, and 11 were given a placebo. Again, the drug and placebo were administered in intravenous doses once a month.

Everyone in this study had severe, prednisone-dependent asthma. Prednisone is an oral steroid that is generally quite effective in treating asthma but has numerous and serious side effects.

In the six-month trial, there were 12 asthma exacerbations in 10 people on placebo. Nine had evidence of eosinophils during their exacerbations. During the study, just one person in the treatment group had an exacerbation, but no eosinophils were present. Additionally, those taking the drug were able to reduce their dosage of prednisone more than people on placebo could.

Mepolizumab was not associated with a serious side effect in either study, though both authors pointed out that the studies were small and no more than six months to a year long.

"If you are one of those people [who has eosinophils] and your asthma is pretty severe, this may be a relatively promising treatment to prevent exacerbations, though it's still experimental," said the author of an accompanying editorial in the same issue of the journal, Dr. Sally Wenzel, director of the Asthma and Allergy Center at the University of Pittsburgh Medical Center.

But, she pointed out that not everyone who has asthma also has eosinophils.

All three experts said they were not sure if mepolizumab would have a place in treating less severe asthma, at least for awhile. O'Byrne said that the drug needs to be studied in larger populations and it's currently very expensive, which would limit its use by people who have other treatment options.

More information

The American Academy of Allergy, Asthma and Immunology has more about asthma.



SOURCES: Paul O'Byrne, M.B., professor and chairman, department of medicine, McMaster University, and executive director, The Firestone Institute, St. Joseph's Hospital, Hamilton, Ontario, Canada; Ian Pavord, D.M., consultant physician and honorary professor, medicine, Glenfield Hospital, University Hospitals of Leicester, U.K.; Sally E. Wenzel, M.D., director, Asthma and Allergy Center, University of Pittsburgh and University of Pittsburgh Medical Center; March 5, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug May Prevent Plaque Buildup
2. Experimental Biology 2009 meets April 18-22
3. Experimental Weight-Loss Pill Passes Early Test
4. Experimental Drug Fights Bone Marrow Cancers
5. Experimental Vaginal Gel Doesnt Ward Off HIV
6. Experimental TB drug explodes bacteria from the inside out
7. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
8. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
9. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
10. Experimental Drug Fights Multiple Sclerosis Activity
11. Experimental Therapy Beats Back One Patients Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug May Dampen Severe Asthma
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the ... pet anxiety. "Pet owners often think anxiety only manifests itself as trembling or ... other ways, and there’s things that be done about it,” says Dr. Jim Lowe, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... it has been selected by Tidelands Health, a three hospital system in South ... be constantly on the lookout for technology that enhances communication, drives workflow efficiencies ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced ... medical situations or practice tricky or rare procedures in an environment that looks and ... Center is also available to inventors and “hackers” to develop and test new devices ...
(Date:5/3/2016)... ... ... Each year, about 800,000 people suffer from cerebral vascular accidents, or strokes. ... for one death every four minutes. Many people who survive a stroke are ... a video series called “Your Brain,” in conjunction with its medical journal “Balance,” in ...
(Date:5/3/2016)... ... 2016 , ... Ogawa World USA introduced the first of its kind ... Smart Application. The Smart 3D combines the best in technological advancement, design, and massage ... and specialized massage program, each user has a tailored experience unparalleled by any other ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
(Date:4/29/2016)... New Jersey , April 29, 2016 /PRNewswire/ ... Software Suite for Life Sciences, Product Development Capabilities ... Global Life Science Customer Base . ... solutions provider, today announced the acquisition of Skura ... a global leader in adaptive sales enablement technology ...
Breaking Medicine Technology: